Skip to main content
Kent Academic Repository

ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein

Rösch, Lisa, Herter, Sonja, Najafi, Sara, Ridinger, Johannes, Peterziel, Heike, Cinatl, Jindrich, Jones, David T. W., Michaelis, Martin, Witt, Olaf, Oehme, Ina and others. (2023) ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein. Molecular Oncology, 17 (1). pp. 37-58. ISSN 1574-7891. (doi:10.1002/1878-0261.13318) (KAR id:97538)


Chemotherapy resistance is a persistent clinical problem in relapsed high-risk neuroblastomas. We tested a panel of 15 drugs for sensitization of neuroblastoma cells to the conventional chemotherapeutic vincristine, identifying tariquidar, an inhibitor of the transmembrane pump P-glycoprotein (P-gp/ABCB1), and the ERBB family inhibitor afatinib as the top resistance breakers. Both compounds were efficient in sensitizing neuroblastoma cells to vincristine in trypan blue exclusion assays and in inducing apoptotic cell death. The evaluation of ERBB signaling revealed no functional inhibition, i.e., dephosphorylation of the downstream pathways upon afatinib treatment but direct off-target interference with P-gp function. Depletion of ABCB1, but not ERRB4, sensitized cells to vincristine treatment. P-gp inhibition substantially broke vincristine resistance in vitro and in vivo (zebrafish embryo xenograft). The analysis of gene expression datasets of more than 50 different neuroblastoma cell lines (primary and relapsed) and more than 160 neuroblastoma patient samples from the pediatric precision medicine platform INFORM (Individualized Therapy For Relapsed Malignancies in Childhood) confirmed a pivotal role of P-gp specifically in neuroblastoma resistance at relapse, while the ERBB family appears to play a minor part.

Item Type: Article
DOI/Identification number: 10.1002/1878-0261.13318
Uncontrolled keywords: chemotherapy resistance, apoptotic cell death, off-target, zebrafish xenograft model, pediatric patient samples, precision medicine
Subjects: R Medicine > RC Internal medicine > RC254 Neoplasms. Tumors. Oncology
R Medicine > RM Therapeutics. Pharmacology
Divisions: Divisions > Division of Natural Sciences > Biosciences
Funders: University of Kent (
Depositing User: Martin Michaelis
Date Deposited: 21 Oct 2022 17:18 UTC
Last Modified: 17 May 2024 14:43 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.